Welcome to Dragonfly Biosciences, Europe’s leading premium retailer of Cannabidiol (CBD).
A research-fuelled and community-minded company, Dragonfly controls the process from seed to sale, guaranteeing the highest and most consistent product quality. We work strictly within the frontiers of current legislation and operate with total transparency, keeping our fields, processing facility, laboratories and products open to consumers.
Currently offering a range of CBD health and lifestyle products, Dragonfly aims to expand its business and product range in line with legal changes in Europe.
As demand grows for CBD health supplements, we will continue to be the go-to producer and supplier of Cannabidiol for both businesses and consumers.
Guaranteed accurate concentration (%) of CBD
Produced under stringent control and tested by independent, accredited labs
Organically certified product
GUARANTEED CUSTOMER CARE
Customer service that can help you before, during and after the purchase
All our products are tested in third-party laboratories, as well as our own to ensure consistency and quality across the board. Dragonfly works under Good Manufacturing Practices (GMP). Our product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a and CBG. We guarantee that our products are 100% organic. Click here to read more…
Radost is an entrepreneur and experienced businesswoman, based in Sofia.
Equipped with a law degree, she spent her early years as head of the Legal Department at Sofia Municipality, responsible for all large-scale urban development, architecture, and infrastructure-focused projects.
Radost has developed a series of solar farms, a successful TV production company and now is dedicated to building Dragonfly Biosciences.
Chris is a serial entrepreneur and investor. With experience in both media and health-related industries.
Chris is acting CEO; having previously been involved in Wellbeing Network, where he also served as a CEO.
In 1991, Chris founded Chello Zone Holdings (also known as Zone Vision Networks) an England-based TV company. Chris served as President; he developed and expanded Zone Vision Networks worldwide.
Chello Zone was sold to Liberty Global and then in 2014 sold to AMC Networks as part of the Chellomedia sale for more than $1.0bn
Chris also ran Sapphire Media, which was sold to (LFP) Larry Flynt Productions and Zone Studios which was sold to BTI.
Mark has over 30 years experience in the media industry; film, television and music.
Initially a kidnap and ransom broker at Lloyds of London, he then became one of the original team members of Henson International Television, the creators of The Muppet Show.
After several productions in TV, music and film, he put together a group that raised US$250m to acquire the International Library Rights to titles in and the Hallmark Channel. This was subsequently acquired by NBCUniversal in 2007.
Subsequently, Mark has multiple investments in digital media.
Regan is a Chartered Accountant with over 20 years of experience in the media industry.
Regan has spent 4 years at NBCUniversal where he served as VP Finance in the Emerging Markets and International Corporate divisions.
Previously, Regan spent 8 years at Chello Zone where he served as CFO supporting the worldwide expansion and the eventual sale of Chellomedia to AMC Networks.
Prior to that, Regan spent 8 years at the BBC where he held various senior finance roles.
Regan qualified with Moore Stephens in 1994
Dermot is a chartered accountant and global executive with over 20 years’ experience leading complex, high-growth, multi-national organizations. He has been Chief Executive Officer of Zone Vision Networks Ltd. since January 2002 and played a key role in building and selling the (US$ 1 billion) company. Fabled for his operational control, commercial creativity and strategic planning, Dermott has helped to grow brands such as CNBC, Discovery, Animal Planet, Food Network, CBS, Extreme Sports, Outdoor Channel, MGM and AMC.
PROF. SAOIRSE O’SULLIVAN
Saoirse brings 15 years of cannabinoid wisdom to the Dragonfly board. Previously serving as Associate Professor at the University of Nottingham, her research is centred in on the endocannabinoid system, with a particular focus on the role it plays in diabetes and obesity. Since 2016, she has been named Young Investigator of the Year by the International Cannabinoid Research Society and acted as a source of expertise for numerous BBC documentaries. A seasoned academic, she will keep us at the cutting edge of new research findings.
DR ANDY YATES
Andy is a pharmacist armed with a PhD in cannabinoid medical chemistry from the University of Nottingham, his own pharmaceutical consultancy and over 15 years’ experience in the industry. He is also the pharmacy lead for the Centre for Medicinal Cannabis and has a wealth of experience in the realms of academia, biotechnology and peer pharma. Andy will keep Dragonfly updated with the latest cannabinoid research insights, including new theories, papers and data.
Paul has more than 25 years leadership experience in the pharmaceutical industry. After spending 14 years at GlaxoSmithKline (GSK), including a stint as the General Manager of Europe, Paul later became the Executive Vice President of Worldwide Commercial Operations at Gilead Sciences Inc. He also spent four years working at Arthur Anderson and is now the board director of several biotech companies, as well as being a Fellow of the UK Chartered Institute of Management Accountants.
In association with